EUVIMEDEUVIMED entdecken
Crossref

Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study

Carl Shultz, Shreyas Shirodkar, Chelby Wakefield, Steven Rollins, Sijin Wen, Kelly Ross, Michael Craig, Aaron Cumpston, Mehdi Hamadani, Abraham S Kanate, Lauren Veltri

Transplantation and Cellular Therapy · 2026-11 · 32 (11) · 1415.e1-1415.e5

DOI: 10.1016/j.jtct.2026.06.034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2026-11. Verfasst von Carl Shultz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, West Virginia. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BusulfanConditioningLymphomaRefractoryStem cell transplantation

Autor:innen und Institutionen

  • Osborn Hematopoietic Malignancy and Cellular Therapy Program, West Virginia University, Morgantown, West Virginia.
  • Department of Internal Medicine, Charleston Area Medical Center, Charleston, West Virginia. Electronic address: shirodkar.sh@gmail.com.
  • Divsion of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of W…

Zitieren

APA

Shultz, C., Shirodkar, S., Wakefield, C., Rollins, S., Wen, S., Ross, K., Craig, M., Cumpston, A., Hamadani, M., Kanate, A. S., & Veltri, L. (2026). Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study. Transplantation and Cellular Therapy, 32(11), 1415.e1-1415.e5. https://doi.org/10.1016/j.jtct.2026.06.034

Vancouver

Shultz C, Shirodkar S, Wakefield C, Rollins S, Wen S, Ross K, et al. Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study. Transplantation and Cellular Therapy. 2026;32(11):1415.e1-1415.e5. doi:10.1016/j.jtct.2026.06.034

BibTeX
@article{Shultz2026,
  author = {Shultz, Carl and Shirodkar, Shreyas and Wakefield, Chelby and Rollins, Steven and Wen, Sijin and Ross, Kelly and Craig, Michael and Cumpston, Aaron and Hamadani, Mehdi and Kanate, Abraham S and Veltri, Lauren},
  title = {Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study},
  journal = {Transplantation and Cellular Therapy},
  year = {2026},
  volume = {32},
  number = {11},
  pages = {1415.e1--1415.e5},
  doi = {10.1016/j.jtct.2026.06.034}
}
Kostenlos starten →